Conference Day One | Wednesday, June 4

7:30 am Check-In & Coffee

8:30 am Chair Opening Remarks

8:40 am Industry leader’s Fireside Chat: Navigating the Path to the Clinic to Accelerate Clinical Efficacy

  • Adrian Bot Founding Chief Scientific Officer & Executive Vice President - Research & Development, Capstan Therapeutics
  • Gilmore O’Neill President & Chief Executive Officer, Editas Medicine
  • Michael Klichinsky Co-Founder & Chief Scientific Officer, Carisma Therapeutics
  • Daniel Getts Chief Executive Officer, Myeloid Therapeutics

Synopsis

  • Discussing preclinical development best practices to supercharge preclinical approval
  • Discussing translational and IND approval challenges
  • Highlighting clinical successes

9:30 am Keynote Presentation: Unveiling Transformative IND Data to Supercharge the Clinical Progression of In Vivo Cell Engineering & Gene Editing Therapies

  • Adrian Bot Founding Chief Scientific Officer & Executive Vice President - Research & Development, Capstan Therapeutics

Synopsis

  • Showcasing IND application data to streamline the IND approval process
  • Evaluating outcomes and identifying key learnings to efficiently and effectively enhance the next wave of clinical progression

10:00 am Morning Break & Speed Networking

Synopsis

As this community reunites, this session will provide valuable networking time with your peers, enabling you to forge new and lasting connections.Β 

11:00 am Keynote Presentation: Highlighting Myeloid’s Groundbreaking Clinical Experience with the First In Vivo CARs Applied to Humans

Synopsis

  • Exploring CAR designs to target myeloid, NK, and T cells to enhance therapeutic precision when combating solid tumorsΒ 
  • Leveraging LNP technology to create a scalable, accessible, cost-effective platformΒ 
  • Uncovering first-in-class phase 1 clinical trial data, demonstrating safety promising clinical benefitsΒ 

11:30 am Elevating Clinical Trial Design to Improve Trial Outcomes & Supercharge Treatment Approval

  • Safi Shahda Senior Director, Medical, Intellia Therapeutics

Synopsis

  • Evaluating clinical trial designs to accelerate treatment progression and approval
  • Leveraging key insights on patient population and data collection to boost clinical trial success
  • Identifying unforeseen challenges in clinical trial development and execution to improve outcomes

12:00 pm Roundtable Discussion: Navigating Clinical Trial Design, Including Treatment Indication & Patient Eligibility

  • Safi Shahda Senior Director, Medical, Intellia Therapeutics

Synopsis

  • Discussing key considerations when selecting appropriate treatment indications
  • Identifying patient eligibility criteria and endpoints to ensure safe, reliable and actionable clinical data
  • Exploring strategies for determining the optimal patient population for viral and non-viral delivery methods

12:45 pm Lunch Break & Networking

1:45 pm Enabling High Precision In Vivo CAR-T Therapy with Targeted Fusogens

  • Dhaval Patel Executive Vice President & Chief Scientific Officer, Sana Biotechnology

Synopsis

  • Comparing methods of cell specific in vivo CAR-T generation.
  • Enabling high precision cell-specific gene editing with Sana’s Fusogen platform, which mediates cell entry via a mechanism that directly couples receptor recognition to cell entry, in contrast to endosomal escape delivery systems.
  • Developing a T cell-specific Fusogen to enable in vivo CAR-T therapy, including in vivo data showing potent and cell-specific CAR-T generation and robust B cell depletion in animal models.

2:15 pm Exploring Treatment Engineering Approaches to Overcome Off-Target Toxicity

  • Bin Wu Founder & Chief Executive Officer, Cytodigm, Inc.

Synopsis

  • Analyzing the antibody approach to targeting and discussing immunogenicity and toxicity produced by antibody conjugation
  • Investigating alternative strategies to enhance targeting and improve safety profiles without antibody conjugation
  • Presenting Cytodigm’s novel approach to target extrahepatic tissues and cell while reducing off-target toxicity

2:45 pm Roundtable Discussion: Overcoming Treatment Uptake by the Liver to Enhance Delivery Efficiency & Prevent Hepatotoxicity

  • Bin Wu Founder & Chief Executive Officer, Cytodigm, Inc.

Synopsis

  • Exploring surface binders as a strategy to de-target the liver and enhance precision
  • Reimagining vehicle design to de-target the liver, improving treatment uptake and delivery efficiency
  • Developing strategies to detoxify the liver to prevent hepatotoxicity and improve patient outcomes

3:30 pm Afternoon Break & Poster Session

Synopsis

This is your opportunity to contribute to the conversation and share your cutting-edge research with this community while discovering exciting work carried out by your peers. To submit a poster, please contact info@hansonwade.com.

4:00 pm Translating & Harnessing Key Learnings from Ex Vivo Therapies to Supercharge In Vivo Clinical Progression

Synopsis

  • Reviewing the translational capacity of current preclinical models to highlight required improvements in model type and size
  • Identifying suitable animal models based on specific therapeutic indications and desired outcomes to produce reliable, translational results and accelerate clinical progression
  • Showcasing the evolution from ex vivo to in vivo CAR Therapies

4:30 pm Investigating Strategies to Refine Translational Outcomes & Direct Future Advancements

  • Gregory Frost Chairman & Chief Executive Officer, Exuma Biotechnology

Synopsis

  • Discussing strategies to effectively triangulate preclinical models to decrease the variability of translational outcomes
  • Showcasing accurate translational data utilizing methods triangulating preclinical models
  • Exploring future advancements in preclinical models to further enhance translational precisionΒ 

4:50 pm Chair’s Closing Remarks

5:15 pm End of Conference Day One